Search

Your search keyword '"Abdul‐Hay, Maher"' showing total 46 results
Start Over Author "Abdul‐Hay, Maher"
46 results on '"Abdul‐Hay, Maher"'

4. First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome

Author

Narayan, Rupa, primary, Piérola, Ana Alfonso, additional, Donnellan, William B., additional, Yordi, Antonieta Molero, additional, Abdul‐Hay, Maher, additional, Platzbecker, Uwe, additional, Subklewe, Marion, additional, Kadia, Tapan Mahendra, additional, Alonso‐Domínguez, Juan Manuel, additional, McCloskey, James, additional, Bradford, Kathryn, additional, Curtis, Martin, additional, Daskalakis, Nikki, additional, Guttke, Christina, additional, Safer, Karim, additional, Hiebert, Brett, additional, Murphy, Joseph, additional, Li, Xiang, additional, Duchin, Ken, additional, and Esteban, Daniel, additional

Published
2024
Full Text
View/download PDF

5. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

Author

Jabbour, Elias, primary, Zugmaier, Gerhard, additional, Agrawal, Vaibhav, additional, Martínez‐Sánchez, Pilar, additional, Rifón Roca, José J., additional, Cassaday, Ryan D., additional, Böll, Boris, additional, Rijneveld, Anita, additional, Abdul‐Hay, Maher, additional, Huguet, Françoise, additional, Cluzeau, Thomas, additional, Díaz, Mar Tormo, additional, Vucinic, Vladan, additional, González‐Campos, José, additional, Rambaldi, Alessandro, additional, Schwartz, Stefan, additional, Berthon, Céline, additional, Hernández‐Rivas, Jesús María, additional, Gordon, Paul R., additional, Brüggemann, Monika, additional, Hamidi, Ali, additional, Chen, Yuqi, additional, Wong, Hansen L., additional, Panwar, Bharat, additional, Katlinskaya, Yuliya, additional, Markovic, Ana, additional, and Kantarjian, Hagop, additional

Published
2024
Full Text
View/download PDF

8. Leukemia Cutis in Relapsed Acute Myeloid Leukemia: A Call for Distinct Classification.

Author

Nahm, William J., Juarez, Michelle, Abdul-Hay, Maher, Bhatt, Ahan, Meehan, Shane A., and Shvartsbeyn, Marianna

Subjects
ACUTE myeloid leukemia, LEUKEMIA, PATHOLOGY, HEMATOLOGIC malignancies, MYELOID cells, PRELEUKEMIA, CANCER remission
Abstract

Objective: Rare coexistence of disease or pathology Background: Acute myeloid leukemia is characterized by dysregulated proliferation and maturation arrest of myeloid precursors, precipitating a spectrum of complications. Among these, leukemia cutis refers specifically to ectopic deposition and proliferation of malignant myeloid cells within the skin. This infiltration pathogenesis remains unclear. Although there are numerous reports of leukemia cutis in the setting of acute myeloid leukemia or primary acute myeloid leukemia, there are no specific reports of leukemia cutis in the setting of relapsed acute myeloid leukemia. Report: A 59-year-old woman, with a history of remission from poor-risk acute myeloid leukemia, previously treated with chemotherapy and allogenic bone marrow transplant, presented with shortness of breath, lethargy, anemia, thrombocytopenia, and subcutaneous nodules on lower extremities. Leukemia cutis was diagnosed, in the setting of relapsed acute myeloid leukemia. After unsuccessful salvage chemotherapy and being deemed unsuitable for further treatment, she pursued palliative care and died a month later. Conclusions: Our case highlights a lack of reporting or making a distinction of those patients with relapsed acute myeloid leukemia and leukemia cutis. Consequently, it can be deduced that patients who simultaneously have relapsed acute myeloid leukemia and leukemia cutis are expected to fare worse in terms of clinical outcomes than those with primary acute myeloid leukemia and leukemia cutis. Relapsed acute myeloid leukemia patients with leukemia cutis should be classified as a distinct group, warranting further research into aggressive therapeutic targets and survival rates, while emphasizing the need for more vigilant follow-up and lower biopsy thresholds for cutaneous lesions in patients with treated hematologic malignancies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. PB1847: A PHASE 1 STUDY TO INVESTIGATE CLN-049, A FLT3/CD3 BISPECIFIC T CELL ENGAGER, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)

Author

Abdul-Hay, Maher, primary, Dinardo, Courtney, additional, Chan, Onyee, additional, Narayan, Rupa, additional, Issa, Ghayas, additional, Michaelson, Jennifer, additional, Baeuerle, Patrick, additional, Meetze, Kristan, additional, Janik, John, additional, Shapiro, Irina, additional, Inumerable, Judy, additional, Jones, Jeffery, additional, and Sallman, David, additional

Published
2023
Full Text
View/download PDF

13. Acute Myeloid Leukemia Treatment in the Elderly: A Comprehensive Review of the Present and Future.

Author

Choi, Jun H., Shukla, Mihir, and Abdul-Hay, Maher

Subjects
ACUTE myeloid leukemia, OLDER patients, OLDER people, HEMATOPOIETIC system, VENETOCLAX, PRELEUKEMIA
Abstract

Background: Acute myeloid leukemia (AML) is a disease of the hematopoietic system that remains a therapeutic challenge despite advances in our understanding of the underlying cancer biology in the past decade. It is also an affliction of the elderly that predominantly affects patients over 60 years of age. Standard therapy involves intensive chemotherapy that is often difficult to tolerate in older populations. Fortunately, recent developments in molecular targeting have shown promising results in treating leukemia, paving the way for novel treatment strategies that are easier to tolerate. Summary: Venetoclax, a BCL-2 inhibitor, when combined with a hypomethylating agent, has proven to be a highly effective and well-tolerated drug and established itself as a new standard for treating AML in patients who are unfit for standard intensive therapy. Other targeted therapies include clinically proven and FDA-approved agents, such as IDH1/2 inhibitors, FLT3 inhibitors, and Gemtuzumab, as well as newer and more experimental drugs such as magrolimab, PI-kinase inhibitors, and T-cell engaging therapy. Some of the novel agents such as magrolimab and menin inhibitors are particularly promising, providing therapeutic options to a wider population of patients than ever before. Determining who will benefit from intense or novel low-intense therapy remains a challenge, and it requires careful assessment of individual patient's fitness and disease characteristics. Key Messages: This article reviews past and current treatment strategies that harness various mechanisms of leukemia-targeting agents and introduces novel therapies on the horizon aimed at exploring therapeutic options for the elderly and unfit patient population. It also provides a strategy to select the best available therapy for elderly patients with both newly diagnosed and relapsed/refractory AML. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. PTCy, Abatacept, and Short Course of Tacrolimus for GvHD Prevention Following Haploidentical Transplantation

Author

Al-Homsi, A Samer, primary, Cirrone, Frank, additional, Wo, Stephanie, additional, Cole, Kelli, additional, Suarez-Londono, J Andres, additional, Gardner, Sharon L, additional, Hsu, Jingmei, additional, Stocker, Kelsey, additional, Bruno, Benedetto, additional, Goldberg, Judith D., additional, Levinson, Benjamin A, additional, and Abdul-Hay, Maher, additional

Published
2023
Full Text
View/download PDF

16. Phase Ib-II Study of Post-Transplant Cyclophosphamide, Abatacept and Short Course of Tacrolimus (CAST) for Graft-Versus-Host Disease Prevention Following Haploidentical Peripheral Blood Stem Cell Transplantation

Author

Samer Al-Homsi, A, primary, Cirrone, Frank, additional, Cole, Kelli, additional, Londono, J Andres-Suarez, additional, Gardner, Sharon, additional, Hsu, Jingmei, additional, Wo, Stephanie, additional, Stocker, Kelsey, additional, Goldberg, Judith, additional, Levinson, Benjamin, additional, and Abdul-Hay, Maher, additional

Published
2023
Full Text
View/download PDF

17. Post-Transplant Cyclophosphamide, Abatacept and Short Course of Tacrolimus (CAST) for Graft-Versus-Host Disease Prevention Following Haploidentical Peripheral Blood Stem Cell Transplantation

Author

Al-Homsi, A Samer, primary, Cirrone, Frank, additional, Cole, Kelli, additional, Suarez-Londono, Jaime Andres, additional, Gardner, Sharon L., additional, Hsu, Jingmei, additional, Wo, Stephanie, additional, Stocker, Kelsey, additional, Bruno, Benedetto, additional, Goldberg, Judith, additional, Levinson, Benjamin, additional, and Abdul-Hay, Maher, additional

Published
2022
Full Text
View/download PDF

20. Poster: ALL-269 Safety and Pharmacokinetics of Calaspargase Pegol in Adults With Newly Diagnosed Philadelphia-Negative Acute Lymphoblastic Leukemia: A Phase 2/3 Study

Author

Stock, Wendy, primary, Park, Jae H., additional, Emadi, Ashkan, additional, Abdul-Hay, Maher, additional, Cassaday, Ryan D., additional, Pullarkat, Vinod, additional, Webster, Jonathan A., additional, Pandya, Susan, additional, Mogul, Mark, additional, Shvenke, Yelena, additional, Zhu, Jian, additional, Tessier, Adrien, additional, and DeAngelo, Daniel J., additional

Published
2022
Full Text
View/download PDF

22. Prescreening to Increase Therapeutic Oncology Trial Enrollment at the Largest Public Hospital in the United States

Author

Wu, Jennifer, primary, Yakubov, Amin, additional, Abdul-Hay, Maher, additional, Love, Erica, additional, Kroening, Gianna, additional, Cohen, Deirdre, additional, Spalink, Christy, additional, Joshi, Ankeeta, additional, Balar, Arjun, additional, Joseph, Kathie-Ann, additional, Ravenell, Joseph, additional, and Mehnert, Janice, additional

Published
2022
Full Text
View/download PDF

23. Post-Transplant Cyclophosphamide, Abatacept, and Short Course of Tacrolimus Combination (CAST) Is Safe and Seems Highly Effective in Preventing Graft-Versus-Host Disease Following Haploidentical Peripheral Blood Stem Cell Transplantation

Author

Al-Homsi, A Samer Samer, primary, Cirrone, Frank, additional, Cole, Kelli, additional, Stocker, Kelsey, additional, Bruno, Benedetto, additional, Suarez-Londono, J Andres, additional, Goldberg, Judith, additional, and Abdul-Hay, Maher, additional

Published
2021
Full Text
View/download PDF

25. Safety and Pharmacokinetics of Calaspargase Pegol in Adults with Newly Diagnosed Philadelphia-Negative ALL: A Phase 2/3 Study

Author

Stock, Wendy, primary, Park, Jae H, additional, Emadi, Ashkan, additional, Abdul-Hay, Maher, additional, Cassaday, Ryan D., additional, Pullarkat, Vinod A., additional, Webster, Jonathan, additional, Pandya, Shuchi S., additional, Mogul, Mark J, additional, Shvenke, Yelena, additional, Zhu, Jian J, additional, Tessier, Adrien, additional, and DeAngelo, Daniel J., additional

Published
2021
Full Text
View/download PDF

27. Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform

Author

Al-Homsi, Ahmad-Samer, primary, Anguille, Sebastien, additional, Deeren, Dries, additional, Nishihori, Taiga, additional, Meuleman, Nathalie, additional, Abdul-Hay, Maher, additional, Morgan, Gareth J., additional, Brayer, Jason, additional, Braun, Nathalie, additional, Lonez, Caroline, additional, Dheur, Marie-Sophie, additional, Alcantar-Orozco, Erik, additional, Gilham, David, additional, Flament, Anne, additional, and Lehmann, Frédéric F., additional

Published
2021
Full Text
View/download PDF

31. Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Author

Al-Homsi, A. Samer, primary, Purev, Enkhtsetseg, additional, Lewalle, Philippe, additional, Abdul-Hay, Maher, additional, Pollyea, Daniel A, additional, Salaroli, Adriano, additional, Lequertier, Thomas, additional, Alcantar-Orozco, Erik, additional, Borghese, Fabian, additional, Lonez, Caroline, additional, Braun, Nathalie, additional, Renard, Florence, additional, Flament, Anne, additional, Moors, Ine, additional, and Kerre, Tessa, additional

Published
2019
Full Text
View/download PDF

34. Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)

Author

Sawas, Ahmed, primary, Elgedawe, Hager, additional, Vlad, George, additional, Lipschitz, Mikel, additional, Chen, Pei-Hsuan, additional, Rodig, Scott J, additional, Lue, Jennifer Kimberly, additional, Deng, Changchun, additional, Amengual, Jennifer E, additional, Abdul Hay, Maher, additional, Khan, Karen, additional, Atkins, Laine E., additional, Rada, Aishling M., additional, Geskin, Larisa, additional, and O'Connor, Owen A., additional

Published
2018
Full Text
View/download PDF

35. Midostaurin in Combination with Idarubicin and Cytarabine (3+7) Induction for FLT3 Positive AML - Very High Complete Response Rates and Transition to Allogeneic Transplantation

Author

Azzi, Jacques, primary, Cirrone, Frank, additional, Abdul Hay, Maher, additional, Kaminetzky, David, additional, Hymes, Kenneth B., additional, Kreditor, Maxim, additional, Al-Homsi, Ahmad-Samer, additional, Grossbard, Michael L., additional, Diefenbach, Catherine, additional, Moskovits, Tibor, additional, Saint Fleur-Lominy, Shella, additional, Raphael, Bruce G., additional, and Tibes, Raoul, additional

Published
2018
Full Text
View/download PDF

36. A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2Aor NPM1Alterations

Author

Jabbour, Elias, Searle, Emma, Abdul-Hay, Maher, Abedin, Sameem, Aldoss, Ibrahim, Alfonso Piérola, Ana, Alonso-Dominguez, Juan Manuel, Chevallier, Patrice, Cost, Carrye, Daskalakis, Nikki, Dillon, Richard, Dunavin, Neil, Esteve, Jordi, Fathi, Amir T., Fedele, Pasquale L., Ferrante, Lucille, Garciaz, Sylvain, Guttke, Christina, Gyan, Emmanuel, Hiebert, Brett, Kwon, Min Chul, Miller, Jonathan, Ng, Teng Fong, Packman, Kathryn, Philippar, Ulrike, Pigneux, Arnaud, Recher, Christian, Salamero, Olga, Sanga, Madhu, Stone, Richard M, Tan, Peter, Thuring, Jan Willem, Tucker, Trevor, and Vyas, Paresh

Abstract

Background:Relapsed/refractory (R/R)acute leukemia withalterations in KMT2A(also called MLL1; 9-15% of adult AML, 10% of ALL) or NPM1(30% of adult AML) are often associated with poor outcomes. Pre-clinical studies demonstrated the relevance of the menin-KMT2A protein-protein interaction in sustaining leukemic cells with KMT2Aand NPM1alterations (Kuhn 2016). JNJ-75276617 is a potent and selective inhibitor of the interaction between the scaffolding protein menin and the methyltransferase KMT2A with preclinical activity in KMT2A-rearranged or NPM1-mutated leukemic cell lines and primary leukemia patient samples in vitroand in vivo(Kwon 2022). We report initial data investigating JNJ-75276617 in adult participants (pts) with R/R acute leukemia harboring KMT2Aalterations (rearrangements, amplifications, or partial tandem duplications) or NPM1mutations.

Published
2023
Full Text
View/download PDF

37. Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study.

Author

Uldrick, Thomas S., Gonçalves, Priscila H., Abdul-Hay, Maher, Claeys, Alisa J., Emu, Brinda, Ernstoff, Marc S., Fling, Steven P., Fong, Lawrence, Kaiser, Judith C., Lacroix, Andreanne M., Lee, Steve Y., Lundgren, Lisa M., Lurain, Kathryn, Parsons, Christopher H., Peeramsetti, Sharavi, Ramaswami, Ramya, Sharon, Elad, Sznol, Mario, Wang, Chia-Ching (Jackie), and Yarchoan, Robert

Published
2019
Full Text
View/download PDF

45. Analysis of the IgA Heavy Chain Repertoire in Multiple Myeloma: Implications for Host-Microbiome Influences

Author

Braunstein, Marc, El Bannoudi, Hanane, Abdul Hay, Maher, Pond, Sergei L.K., and Silverman, Gregg J.

Abstract

Background: Advances in understanding the biology of multiple myeloma (MM) have translated into novel treatment paradigms that have prolonged survival. Nevertheless, relapse remains common even in the absence of measurable residual disease. Therefore, further research is required to identify additional mechanisms underlying MM pathogenesis, particularly in high-risk subtypes. IgA MM represents approximately 20% of cases and for unclear reasons confers a worse prognosis. Given the physiologic inter-relationships of host IgA with microbiota, we first characterized IgA levels in MM patients and then used a highly sensitive next generation sequencing (NGS) technique for genetic-structural analyses to provide possible insights into selection biases in IgA heavy chain usage that may suggest common antigenic exposures.

Published
2017
Full Text
View/download PDF

46. Impact of Palliative Care Referrals on End-Of-Life Outcomes in Patients with Advanced Hematologic Malignancies.

Author

Seecof, Olivia M., Jang, Charley Q., Kim, Arum, and Abdul-Hay, Maher

Subjects
*PALLIATIVE treatment, *HEMATOLOGIC malignancies, *EMERGENCY room visits, *ADVANCE directives (Medical care), *CANCER patient care, *TREATMENT effectiveness, *DOCUMENTATION
Abstract

1. Participants will be able to identify specific outcomes influencing the importance of early specialty palliative care referrals in patients with advanced hematologic malignancies. 2. Participants will be able to apply principles learned during the presentation to their own practice to improve delivery of palliative care to patients with advanced hematologic malignancies. Palliative care is underutilized in patients with advanced hematologic malignancies. These patients can experience significant physical and psychosocial symptoms due to illness and intensive treatments. This study evaluates the timing and impact of palliative care referrals on end-of-life outcomes to improve the utilization of palliative care in this population. Palliative care is an integrated part of standard oncology practice. Compared to patients with solid malignancies, less is known about the role of palliative care in patients with hematologic malignancies, leading to the underutilization of palliative care for this population. This study evaluates the timing of inpatient and palliative care referrals and the impact on end-of-life outcomes over a 5-year period to improve the utilization of palliative care in patients with advanced hematologic malignancies. This study compares end-of-life outcomes among patients who receive early specialty palliative care consults to those who receive late or no referral to palliative care. The primary outcome measure is hospitalization rates in the last 14 days of life. Secondary outcome measures include the documentation of advance care planning conversations and choices, in-hospital deaths, non-hospital deaths, hospice referrals, emergency room visits, intensive care unit admissions and disease-directed therapies in the last 14 days of life. This is a retrospective cohort of patients aged 18 and older with a diagnosis of acute leukemia, multiple myeloma with at least 4 lines of therapy, or high-risk lymphoma seen at an academic cancer center between July 1, 2018-June 30, 2023. Patients were separated into groups of early, late, or no specialty palliative care referrals. Kaplan Meier estimates and Cox proportional hazards regression models will be used to examine variables associated with timing of palliative care referral. Groups will be compared using the t-test, Mann-Whitney test, chi-square test or Fisher exact test depending on the examined variables. With approval, results will be available and presented at the conference. This study evaluates the timing of palliative care referrals and the impact on end-of-life outcomes over a 5-year period to improve the utilization of palliative care in patients with advanced hematologic malignancies. Disease specific management / Models of Palliative Care Delivery [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results